| Date | Title | Description |
| 12.07.2024 | Beacon Therapeutics Secures $170 Million in Series B Funding for Advancement of Ophthalmic Gene Therapies | Beacon Therapeutics, a pioneering ophthalmic gene therapy company, has achieved a significant milestone by raising a substantial $170 million in Series B funding. This funding round, spearheaded by Forbion and bolstered by the support of Sy... |
| 03.07.2024 | Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial | Beacon Therapeutics has raised a $170 million series B, which the U.K.-based gene therapy biotech will use to push its eye disease candidates through clinical trials.
London-based Beacon (which also has a base in Massachusetts) launched wit... |
| 03.07.2024 | Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies | Financing led by life sciences venture capital firm Forbion, alongside existing investors Syncona and Oxford Science Enterprises, as well as new investors TCGX and Advent Life Sciences
Round will accelerate the development of lead asset AGT... |
| 25.06.2024 | iOnctura's Precision Cancer Treatments Gain Momentum | iOnctura, a clinical-stage biopharmaceutical company based in Amsterdam, recently secured EUR80 million in Series B financing to accelerate the development of their lead asset, roginolisib, for the treatment of uveal melanoma and other onco... |
| 24.06.2024 | iOnctura closes EUR80 million Series B financing |
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces that it has closed an EUR80 million Series B financing. The funding round was led by new investor Syncona Limited with part... |
| 17.06.2024 | Syncona merges Freeline and SwanBio to spur new gene-therapy-focused biotech | Seven months after Syncona threw a financial lifeline to struggling Freeline Therapeutics, the London-based investment firm is giving the biotech another present in the form of fellow gene therapy company SwanBio.
Both Freeline and SwanBio ... |
| 07.02.2023 | Investor Syncona blames bear market's ravaging of British biotechs for 'disappointing' returns | Life sciences investment firm Syncona has blamed a “disappointing” drop in returns on plummeting share prices for British biotechs across its portfolio in December.
The London-based company ended 2022 with net assets of £1.29 billion ($1.55... |
| 24.10.2022 | Syncona To Buy Applied Genetic Technologies, for Up to $73.5M | A newly established portfolio company of Syncona Limited (LON: SYNC), a London, UK-based healthcare company focused on founding, building and funding global leaders in life science, is to acquire Applied Genetic Technologies Corporation (Na... |
| 15.07.2022 | Former Spark exec to lead a gene therapy upstart of his own; Big Pharma marketing vet named CEO of Swiss biotech | Joseph La Barge
→ Dave Greenwald’s days as acting CEO of Apertura Gene Therapy are over as Joseph La Barge steps in to lead the biotech, which just launched in April.
Peer Review had been wondering about La Barge’s next landing sp... |
| 18.02.2022 | Amgen, Ipsen vet moves up the ladder with Coherus' anti-PD-1 awaiting PDUFA; It takes a village to replace Frank Clyburn at Merck's Human Health business | Paul Reider
After decades in the biopharma industry, Paul Reider is now in his first C-suite role as chief commercial officer. While he has been at Coherus BioSciences since last year, he officially started his new job on Jan. 1, and it was... |
| 04.02.2022 | Syncona : Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (2) | LONDON, February 3, 2022 - Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inh... |
| 10.01.2022 | Syncona : Autolus announces 2022 priorities | obe-cel has the potential to transform outcomes for adult ALL patients
Phase 2 FELIX study data expected in 2022
LONDON, January 10, 2022 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next... |
| 07.01.2022 | Syncona : Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (1) | LONDON, January 6, 2022 - Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients sufferi... |
| 06.01.2022 | Syncona : Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1 | FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1
FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022
LONDON, January 6, 2022 - Freeline Therapeut... |
| 16.12.2021 | Anaveon raises CHF 110 million | |
| 29.11.2021 | Syncona : Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |
| 12.11.2021 | Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting | ANV419 demonstrates highly promising safety profile
November 12, 2021 - Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on its lead program ANV419 at the Society for Immunotherapy of Cancer'... |
| 11.11.2021 | Syncona Interim Results for the six months ended 30 September 2021 | Continued focus on hands-on engagement with a maturing portfolio with key milestones ahead
Syncona Ltd, ("Syncona"), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life scie... |
| 11.11.2021 | Syncona Interim Results for the period ending 30 September 2021 | 11 November 2021
Syncona Limited
Interim Results for the six months ended 30 September 2021
Continued focus on hands-on engagement with a maturing portfolio with key
milestones ahead
Key highlights
Net assets of £1,152.8 million (31 March 2... |
| 27.10.2021 | Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy | First clinical trial will investigate QEL-001 as a novel treatment to prevent organ rejection in liver transplant patients and eliminate the need for lifelong systemic immunosuppression
Quell Therapeutics Ltd ("Quell"), the world ... |
| 24.09.2021 | Syncona : Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult | Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell's pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity
Quell Therapeutics Ltd (&q... |
| 02.09.2021 | Syncona : Purespring strengthens senior leadership with appointment of Chief Medical Officer and Chief Development Officer | Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, announces the appointments of Dr Ronny Renfurm as Chief Medical Officer (CMO) and Julian Hanak as Chief Development Officer... |
| 17.08.2021 | Syncona : announces First Quarter Update | We are pleased with the continued positive clinical progress across our companies over the period, with five clinical stage businesses now within the Syncona portfolio
Syncona Ltd, a leading healthcare company focused on founding, building ... |
| 17.08.2021 | Syncona : Quarterly Update covering the period from 31 March 2021 to 30 June 2021 | Syncona Limited
First Quarter Update
17 August 2021
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today issues its quarterly update covering the period fro... |
| 22.07.2021 | Syncona : Quell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer | Dr. Hartl, former Therapeutic Area Head - Autoimmunity/Transplantation/Inflammation at Novartis Institutes for Biomedical Research (NIBR), to lead Quell's innovative multi-modular Treg cell therapy programs into clinical development
Quell T... |
| 28.06.2021 | Globus Maritime Limited : Announces Pricing of $50 Million Registered Direct Offering | GLYFADA - Globus Maritime Limited (the 'Company' or 'Globus') (NASDAQ: GLBS) announced today that it has entered into a securities purchase agreement with certain unaffiliated institutional investors to issue 10.0 million of its common shar... |
| 17.06.2021 | SYNCONA LIMITED
Syncona : Final Results for the period ending 31 March 2021 | 17th June 2021
Syncona Limited
Final Results for the Year Ended 31 March 2021
Good progress despite challenging backdrop with positive momentum across an expanded
portfolio of 11 companies
Syncona Ltd, ("Syncona"), a leading healt... |
| 17.06.2021 | Syncona : Final Results for the Year Ended 31 March 2021 | Good progress despite challenging backdrop with positive momentum across an expanded portfolio of 11 companies.
Syncona Ltd, ('Syncona'), a leading healthcare company focused on founding, building and funding a portfolio of global leaders i... |
| 17.06.2021 | Syncona : Final Results for the period ending 31 March 2021 | 17th June 2021
Syncona Limited
Final Results for the Year Ended 31 March 2021
Good progress despite challenging backdrop with positive momentum across an expanded
portfolio of 11 companies
Syncona Ltd, ("Syncona"), a leading healt... |
| 17.06.2021 | SYNCONA LIMITED
Syncona : Final Results for the Year Ended 31 March 2021 | Good progress despite challenging backdrop with positive momentum across an expanded portfolio of 11 companies.
Syncona Ltd, ('Syncona'), a leading healthcare company focused on founding, building and funding a portfolio of global leaders i... |
| 04.05.2021 | Syncona : Achilles Corporate Presentation - May 2021 | Achilles Therapeutics
Precision T cell therapies to treat solid tumors
May 2021
non-confidential © Achilles Therapeutics plc 2021
Forward-Looking Statements
This presentation contains express or implied forward-looking statements that are b... |
| 04.05.2021 | SYNCONA LIMITED
Syncona : Achilles Corporate Presentation - May 2021 | Achilles Therapeutics
Precision T cell therapies to treat solid tumors
May 2021
non-confidential © Achilles Therapeutics plc 2021
Forward-Looking Statements
This presentation contains express or implied forward-looking statements that are b... |
| 20.04.2021 | GEOPARK LIMITED
GeoPark Limited : Announces the Successful Early Tender Results of Its Cash Tender Offer for up to US$255,000,000 of Its 6.500% Senior Notes Due 2024 and Solicitation of Consents for ... | GeoPark Limited (“GeoPark” or the “Company”) (NYSE: GPRK), an exempted company incorporated under the laws of Bermuda announced today the early tender results of its previously announced (i) tender offer to purchase for cash (the “Tender Of... |
| 16.04.2021 | Novavax CFO Greg Covino makes a quick exit as leadership carousel keeps turning; Kite execs fly away to a cell therapy upstart teaming up with Lyell | Greg Covino
→ If it seems like Covid-19 vaccine bridesmaid Novavax is shuttling staffers in and out, you’re not alone. This week, Greg Covino announced he’s leaving the biotech after holding the CFO job for a blink-and-you-miss-it... |
| 06.04.2021 | GEOPARK LIMITED
GeoPark Limited : Announces Tender Offer for up to U.S.$255,000,000 of Its 6.500% Senior Notes Due 2024 and Solicitation of Consents for Proposed Amendments to the Related Indenture | GeoPark Limited (“GeoPark” or the “Company”) (NYSE: “GPRK”), an exempted company incorporated under the laws of Bermuda announced today that it commenced a tender offer to purchase for cash (the “Tender Offer”), up to U.S.$255,000,000 aggre... |
| 01.04.2021 | SYNCONA LIMITED
Syncona : Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL | 'We are pleased to have received PRIME designation for AUTO1 as it will accelerate the review of a promising therapy targeting unmet medical need,' said Dr. Christian Itin, chairman and chief executive officer of Autolus. 'The designation c... |
| 25.03.2021 | SYNCONA LIMITED
Syncona : Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing and clinical activity of AVN419 in patients with solid tumors | Anaveon, a clinical stage, immuno-oncology company, today announced that its Clinical Trial Application (CTA) has been accepted by the Spanish Agency of Medicines and Medical Devices (AEMPS) to conduct a Phase I/II study evaluating the safe... |
| 08.01.2021 | Alkermes promotes from within to find new CFO and COO in rebound effort; Moderna vet Robert Dolski joins Checkmate as CFO | Iain Brown
→ Vowing to find a groove after a string of bogeys on the scorecard, Richard Pops has shaken up the C-suite at Alkermes, staying in-house by tapping Blair Jackson as COO and Iain Brown as CFO. Jackson, who began his t... |
| 19.11.2020 | SYNCONA LIMITED
Syncona : Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours... | Achilles Therapeutics ('Achilles'), a clinical-stage biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced it has raised £52.7 million in an oversubs... |
| 19.11.2020 | Syncona : Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours | Achilles Therapeutics ('Achilles'), a clinical-stage biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced it has raised £52.7 million in an oversubs... |
| 16.09.2020 | SYNCONA LIMITED
Syncona : Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies | Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised $110 million in a Series A financing. The f... |
| 31.07.2020 | Tetraphase deal done, La Jolla Pharmaceutical taps Larry Edwards as CEO; Longtime Eli Lilly exec Michael Overdorf heads to Annexon as CBO | Larry Edwards
→ As La Jolla Pharmaceutical closed on their acquisition of Tetraphase on Wednesday, the San Diego biotech also announced that they’re taking the president and CEO right along with them as Larry Edwards steps... |
| 08.04.2020 | Keytruda nabs another priority review; Quell ties up CAR pact with Hannover Medical School | → Add another priority review for Merck’s Keytruda. Unlike most FDA submissions, this one comes not for a particular cancer type but for tumors with a particular biomarker, known as tumor mutational burden-high, or... |
| 23.03.2020 | VC shop Syncona warns of company trial delays as COVID-19 pandemic deepens | Life science venture capital firm Syncona is warning of serious delays to studies across its biotech portfolio.
The British company said that as COVID-19 sweeps across Europe and the U.S. and with more and more countries issuing tougher loc... |
| 23.03.2020 | VC shop Syncona warns of company trial delays as COVID-19 pandemic deepens | Life science venture capital firm Syncona is warning of serious delays to studies across its biotech portfolio.
Sponsored by Agilent Technologies
How would you like to win free bench space at Lab Central for one scientist for an entire year... |
| 14.06.2019 | Tariq Kassum jumps from Obsidian to Celsius helm; Quell Therapeutics taps Iain McGill as new CEO | Tariq Kassum Linkedin
→ Cambridge, Massachusetts-based Celsius Therapeutics — which was launched in 2018 and backed by Third Rock Ventures and GV — has tapped Tariq Kassum to the helm. Kassum succeeded Alexis Borisy, who has ... |
| 20.05.2019 | UCLTF completes £1m investment into Quell Therapeutics as part of £35m Series A round | Syncona announces the foundation of Quell Therapeutics, a new cell therapy company, with a £35 million commitment in a Series A financing of which Syncona has committed £34 million with a further £1 million being contributed by UCL Technolo... |
| 27.02.2019 | UZH spinoff secures CHF 35 million Series A financing | |
| 26.02.2019 | Amicus blueprints growth plans for Philly-based gene therapy group; Cash-strapped Compugen restructures, cuts 35 staffers | → As Roche puts down its foot in Philadelphia as the base for its budding gene therapy operations built around new subsidiary Spark Therapeutics, Amicus $FOLD is blueprinting its own gene therapy group in the city.
Jeff Cas... |
| 06.07.2017 | UK-based biotech firm Nightstar raises $45 million Series C | London-based Nightstar, a company that develops treatments for retinal diseases, raised $45 million in funding from several investors including Wellington Management Company, Redmile Group, Syncona, and New Enterprise Associates in a Series... |
